Skip to main content

View full-text article in PMC

. 2018 Jul 11;20:72. doi: 10.1186/s13058-018-1001-3

Table 2.

Characteristics of patients with early (< 3 years) and late (≥ 5 years) relapse

	Early (< 3 years)		Late (≥ 5 years)
Characteristic	Number	Percentage	Number	Percentage	P
Number of patients	23	17	20	15
Age (years)					ns^a
Median	55		53
Range	27–75		38–74
Menopausal status					ns^a
Premenopausal	8	34.8	7	35
Postmenopausal	15	65.2	13	65
Tumor size (cm)					ns^a
T1	7	30.4	8	40
T2	12	52.2	10	50
T3	4	17.4	2	10
Histological grade					ns^a
I	0		0
II	10	43.5	6	30
III	12	52.2	14	70
Lobular	1	4.3
Infiltrated lymph nodes					ns^a
0	7	30.4	3	15
1–3	9	39.2	6	30
≥ 4	7	30.4	11	55
ER					< 0.001^a
Positive	9	39.2	19	95
Negative	14	60.8	1	5
PR					0.006^a
Positive	10	43.5	17	85
Negative	13	56.5	3	15
Unknown
HER2					ns^a
Positive	4	17.4	4	20
Negative	18	78.3	16	80
Unknown	1	4.3
Adjuvant chemotherapy					ns^a
Anthracyclines-based	2	8.7	2	10
Taxanes+anthracyclines	16	69.6	17	85
Taxane-based	5	21.7	1	5
Hormone therapy					0.002^a
Yes	12	52.2	19	95
No	11	47.8	1	5

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, ns not significant

Pearson’s chi-squared test for comparison between patients with relapse and without relapse